Biyoyararlanım Çalışmalarının Tasarımı: Mutlak ve Göreceli Biyoyararlanım

Absolute bioavailability (Fabs) measures the proportion of active drug reaching systemic circulation after extravascular administration, such as oral dosing, compared to intravenous administration, which represents 100% bioavailability. Relative bioavailability (Frel) compares systemic drug exposure between a test formulation and a reference formulation. Both are calculated as dose-normalized ratios of their respective area under the curve values.

Absolute bioavailability for oral drugs is computed as the dose-corrected ratio of extravascular drug area under the curve to intravenous drug area under the curve. The resulting Fabs value ranges from 0 to 1, representing systemic absorption rates from 0% to 100%. This calculation accounts for differences in administered doses between routes to provide an accurate comparison of drug absorption efficiency.

Relative bioavailability studies ensure new formulations maintain consistent systemic drug bioavailability compared to approved reference formulations already in clinical use. These studies are essential for assessing generic drugs and alternative delivery systems, confirming therapeutic equivalence between formulations. They help maintain clinical efficacy and safety profiles while supporting regulatory submissions and approval processes.

The area under the drug plasma concentration-versus-time curve (AUC) is the mandatory measurement for regulatory bioavailability submissions. AUC quantifies total systemic drug exposure and serves as the basis for calculating both absolute and relative bioavailability values. Comparing dose-normalized AUC values between different administration routes or formulations determines the proportion of active drug reaching systemic circulation.

Bioavailability studies characterize food effects and drug-drug interactions by measuring oral drug bioavailability under different conditions: with and without food, or with and without interacting drugs. These evaluations determine how concurrent substances influence systemic drug availability. Results guide dosing recommendations and co-administration practices, optimizing therapeutic outcomes and minimizing adverse effects in clinical settings.

An Fabs value of 0.5 indicates that 50% of the administered oral dose reaches systemic circulation compared to intravenous administration. Since Fabs ranges from 0 to 1, representing 0% to 100% systemic absorption, a value of 0.5 reflects moderate bioavailability through the oral route. This suggests that first-pass metabolism, permeability limitations, or other physicochemical factors reduce the proportion of active drug entering systemic circulation.

Intravenous administration is the reference standard because it delivers 100% of the drug directly into systemic circulation, bypassing absorption barriers and first-pass metabolism. This provides a baseline for comparing systemic exposure achieved through other routes. All extravascular bioavailability calculations are normalized against intravenous AUC values, making it the gold standard for assessing drug delivery efficiency through alternative administration routes.